Mizuho reiterates Harmony Biosciences stock rating after litigation
Mizuho reiterated an Outperform rating and $51 price target for Harmony Biosciences (HRMY) after patent litigation arguments. The stock fell 6% post-arguments, but Mizuho sees no clear negative outcome. HRMY reported strong Q2 2026 earnings, with $1.28 adjusted profit per share and $261.3M revenue, beating estimates. The company maintained full-year revenue guidance of $1B-$1.04B. Other analysts also reiterated positive ratings but adjusted targets.
How this was made
The 30-second read
Why it matters
Analyst coverage remains positive, but the lack of new guidance or material change limits trading relevance.
Market read
The article provides a recap of analyst opinions after earnings and litigation updates, offering minimal new trading insight.
What to watch
Potential upside from strong Q2 earnings and record Wakix revenue not fully reflected in the $51 target.
Background
Harmony Biosciences reported strong Q2 results and a leadership transition while facing ongoing patent litigation over its Wakix product.
Ticker impact
Mizuho reiterated an Outperform rating and a $51 price target for Harmony Biosciences after closing arguments in its Wakix patent litigation.
modest upside pressure as the rating stays positive despite recent weakness
The rating and target are unchanged from prior coverage; the market has already priced the litigation risk, so impact is limited.
Market effects
Little effect on the broader biotech sector; the litigation update is company‑specific.
No regional impact.
Limited to investors tracking HRMY.
Counterpoint
The reiteration may be overly cautious; the stock could rebound if the litigation outcome is favorable.
Key entities
- companyHarmony Biosciences Holdings Inc.
Biopharma developing the Wakix nasal spray for narcolepsy.
- analystMizuho
Equity research firm reiterating Outperform rating.
